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Abstract
Background: Real-time functional magnetic resonance imaging (rtfMRI) is used for neurofeedback training (NFT).
Preliminary results suggest that it can help patients to control their symptoms. This study uses rtfMRI NFT for
relapse prevention in alcohol dependence.
Methods/design: Participants are alcohol-dependent patients who have completed a detoxification programme
within the past 6 months and have remained abstinent. Potential participants are screened for eligibility, and those
who are eligible are randomly assigned to the treatment group (receiving rtfMRI NFT in addition to treatment as
usual) or the control group (receiving only treatment as usual). Participants in both groups are administered
baseline assessments to measure their alcohol consumption and severity of dependence and a variety of
psychological and behavioural characteristics that are hypothesised to predict success with rtfMRI NFT. During the
following 4 months, experimental participants are given six NFT sessions, and before and after each session various
alcohol-related measures are taken. Participants in the control group are given the same measures to coincide with
their timing in the experimental group. Eight and 12 months after the baseline assessment, both groups are
followed up with a battery of measures. The primary research questions are whether NFT can be used to teach
participants to down-regulate their brain activation in the presence of alcohol stimuli or to up-regulate their brain
activation in response to pictures related to healthy goal pursuits, and, if so, whether this translates into reductions
in alcohol consumption. The primary outcome measures will be those derived from the functional brain imaging
data. We are interested in improvements (i.e., reductions) in participants’ alcohol consumption from pretreatment
levels, as indicated by three continuous variables, not simply whether or not the person has remained abstinent.
The indices of interest are percentage of days abstinent, drinks per drinking day, and percentage of days of heavy
drinking. General linear models will be used to compare the NFT group and the control group on these measures.
Discussion: Relapse in alcohol dependence is a recurring problem, and the present evaluation of the role of rtfMRI
in its treatment holds promise for identifying a way to prevent relapse.
Trial registration: ClinicalTrials.gov Identifier: NCT02486900, registered on 26 June 2015.
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Background
There has been a longstanding interest in the use of bio-
feedback in the treatment of a variety of medical and
psychiatric disorders. The basic principle of biofeedback
is that if patients are provided with feedback about the
normally involuntary and uncontrollable physiological
responses associated with their illness, they can use
mental strategies to control these responses and thereby
improve their symptoms [1].
During the 1970s, there was a surge of interest in bio-
feedback using electroencephalography (EEG) Clinical
syndromes for which it was attempted included tension
headache, hypertension, chronic anxiety, and eating
disorders. Although promising results were obtained,
certain methodological problems prevailed, especially
small sample sizes and the absence of satisfactory con-
trol conditions [2]. Thus, definitive conclusions about
the efficacy of biofeedback could not be reached. Never-
theless, the interest in it prevailed into the 1980s and be-
yond, and at this time there was an increase in the
number of ailments for which it was used. Additionally,
EEG biofeedback was extended to cognitive enhancement
and skill training for musicians and dancers and even sur-
geons, again with promising results. Today various kinds
of biofeedback are being offered in certain countries for a
variety of clinical problems, including addiction, anxiety,
attention deficit/hyperactivity disorder (ADHD), depres-
sion, epilepsy, asthma, and chronic pain [3].
In the past decade, there has been a revival of scientific
interest in biofeedback and its clinical applications, partly
driven by the development of real-time functional mag-
netic resonance imaging (rtfMRI) neurofeedback training
(NFT). For NFT, rtfMRI has advantages over EEG. For ex-
ample, it localises brain signals to specific areas of the
brain with more precise resolution, and it capitalises on
the fact that relevant brain areas can be activated when
patients only imagine particular events happening (e.g.
moving a limb of the body, having a drink of alcohol).
rtfMRI NFT has already been used in pilot studies to help
patients with a variety of disorders to ameliorate their
symptoms or unwanted behaviour. These include patients
with debilitating pain [4], Parkinson’s disease [5], depression
[6], and nicotine addiction, or alcohol [7–10]. The feedback
that patients receive about their brain reactions and their
ability to regulate them seems to have an added benefit in
that it helps them to acquire a sense of control over their
symptoms (e.g. [8]). Despite these promising initial results,
additional research is needed to identify (1) variables that
determine the effectiveness of rtfMRI NFT, and (2) optimal
strategies for using it in clinical applications.
BRAINTRAIN: taking imaging into the therapeutic domain
BRAINTRAIN (http://www.braintrainproject.eu/) is a
research project supported by the European Commission
under the Health Cooperation Work Programme of the 7th
Framework Programme that is seeking to achieve these
goals. BRAINTRAIN, coordinated by coauthor DL at
Cardiff University, is a 4-year project to (1) further test
whether rtfMRI is an effective additional form of treatment
for people suffering from a variety of mental and behav-
ioural disorders, and (2) identify variables that determine
the effectiveness of rtfMRI NFT. The disorders that are
being investigated include autism spectrum disorder
(Universidade de Coimbra, Portugal), alcohol dependence
(Cardiff University), posttraumatic stress disorder (Tel Aviv
University, Israel), binge-eating disorder (Eberhard Karls
Universität Tübingen, Germany), and childhood anxiety
(University of Oxford/King’s College London).
The purpose of the present article is to describe the
component of this research programme that is being
conducted at Cardiff University. It is an early phase ran-
domised feasibility trial to assess the effectiveness of
rtfMRI NFT in the treatment of alcohol dependence.
Study objectives
The main aims of the Cardiff arm of BRAINTRAIN are
(1) to determine whether participants who receive rtfMRI
NFT can down-regulate their brain activation while they
are exposed to alcohol stimuli (or up-regulate their brain
activation in response to pictures related to healthy goal
pursuits), and (2) to determine whether, compared to con-
trol participants, the training helps patients to reduce their
urges to drink and their consumption of alcohol and to
bring about other improvements in their functioning.
Additionally, secondary aims of the trial are to (1) identify
participant characteristics that are related to success with
the training, and (2) refine the parameters of the training
in order to achieve an optimal intervention.
Methods
Ethical, safety, and privacy issues
The Wales Research Ethics Committee 1 approved the
research protocol (Ref: 14/WA/1172). Additionally, the
Research and Development Committee at Cwm Taf
University Health Board, Cardiff and Vale University Health
Board, and Aneurin Bevan University Health Board ap-
proved the protocol. Plans for modifying the trial protocol
are unforeseen; however, should they arise, approval will be
sought from the relevant ethics committees. Cardiff Univer-
sity as sponsor of the trial reserves the right to audit trial
conduct should they have any concerns regarding conduct
or safety. The South East Wales Trials Unit (SEWTU) is
providing oversight of trial conduct. The protocol was
designed in accordance with the SPIRIT (Standard Protocol
Items: Recommendations for Interventional Trials) guide-
lines for interventional trials (Additional File 1).
A magnetic resonance imaging (MRI) safety-screening
questionnaire is used to screen potential participants for
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MRI scanning. Patients who have contraindications for
MRI scanning, such as metal implants in their bodies,
are excluded. All information and data obtained from
participants during the course of the study will be kept
confidential by the research team in accordance with the
UK Data Protection Act 1998.
Design
The study is an unblinded, early-phase randomised feasi-
bility trial that includes an experimental group and a
control group of alcohol-dependent participants. The ex-
perimental group (n = 25) receive fMRI NFT in addition
to treatment as usual (TAU). The control group (n = 25)
receive only TAU. Randomisation is balanced for time
since detoxification (more than 3 months, less than 6
months). The South East Wales Trials Unit is providing
an online randomisation programme. A flowchart show-
ing the sequence of recruitment, assessment, and inter-
vention is shown in Fig. 1. A Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
diagram of the study period is shown in Table 1.
Participant eligibility, recruitment, and screening
Eligible participants are alcohol-dependent patients who
have successfully completed an inpatient detoxification
programme 1 to 6 months before enrolment and are cur-
rently enrolled as outpatients. The programmes through
which patients have been detoxified include those run by
the Cwm Taf University Health Board, Cardiff and Vale
University Health Board, and Aneurin Bevan University
Health Board. Additional recruitment sites might be added
at a later time. The TAU that patients receive includes
psychological support, psychoeducation, and medical man-
agement of abstinence, for example with anticraving medi-
cation or disulfiram. Participants are randomly assigned to
(1) a control group who continue to receive only TAU, or
(2) an experimental group who receive rtfMRI NFT in
addition to TAU.
Potential participants’ diagnosis of alcohol dependence
(International Classification of Diseases, tenth edition
(ICD-10): F102) is confirmed by inspection of their clin-
ical records. Patients meeting this criterion are initially
identified and approached to judge their interest in and
suitability for participating in the study. These contacts
are made either by (1) clinicians who are directly in-
volved in the care of the patients, or (2) staff from the
Health and Care Research Workforce in Wales.
Patients who are identified as suitable for the study are
either invited personally by their primary clinician or
they are sent a letter of invitation by their clinical team.
Patients are also offered the opportunity to obtain more
information about the study and to ask questions at in-
formational events called open days, which are organised
at the recruitment sites. During the open days, one or
more members of the research team present details
about the procedures and practicalities of the study
(e.g. scanning procedures, questionnaires that are
being used).
Assessed for eligibility
Excluded if
Inclusion criteria not met
Declined to participate
Follow-up
4 months after baseline assessment
8 months after baseline assessment
12 months after baseline assessment
Experimental group
Receives rtfMRI neuofeedback training 
across four months Plus
Treatment as usual
Follow-up
4 months after baseline assessment 
8 months after baseline assessment
12 months after baseline assessment
Control group
Receives treatment as usual
Allocation
Follow-Up
Randomized
Enrollment
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the phases of the BRAINTRAIN trial
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Once suitable patients have indicated an interest in par-
ticipating in the study, they are invited to visit either one of
the community alcohol and drug clinics or our research la-
boratory at Cardiff University. In either case, a research offi-
cer will give patients an information sheet about the study
procedure, and will also ask participants to provide written
informed consent to participate in the study (see Additional
Files 2 and 3). If consent is obtained, participants are asked
to complete several screening assessments as follows:
1. The Mini International Neuropsychiatric Interview
(MINI; [11]) is a short, structured interview for
diagnosing psychiatric disorders based on Diagnostic
and Statistical Manual of Mental Disorders, fourth
edition (DSM-IV) and ICD criteria. Only the
psychosis section of the MINI is administered.
Patients identified as having a history of a psychotic
disorder not related to alcohol dependence are
excluded from participating
2. The Wechsler Abbreviated Intelligence Scale
(WASI-II; [12]) provides a global measure of
patients’ level of intellectual functioning. Participants
with an IQ below 70 are excluded because they
would likely find the experimental tasks too difficult
to complete
3. An in-house drug-use questionnaire measures par-
ticipants’ use of illicit substances. Patients who have
on-going regular use of illicit drugs, except for can-
nabis, are excluded
4. The Alcohol Timeline Followback (TLFB)
Questionnaire [13] is used to determine whether
patients have drunk alcohol since their discharge
from their detoxification programme. Patients who
have drunk any alcohol are excluded
Participants are informed that they are free to with-
draw from the study at any time.
Baseline assessment
During the baseline assessment, participants complete the
following instruments: a demographic questionnaire (which
asks about participants’ age, gender, level of education, and
socioeconomic status); a National Health Service (NHS) re-
sources utilisation questionnaire (which asks about the use
of prescription medications and treatment services); and
various standardised measures which are shown in Table 2.
Patients are randomised after the baseline session.
Assessment at NFT sessions
At each of the six NFT sessions across 4 months, patients
in the experimental group complete the Drinking Urges
Questionnaire (before and after the MRI scan), a self-
rating of craving during the scanning session, the Alcohol
TLFB (only after the last training session and covering the
Table 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram
Study period
Enrolment Allocation
Timepoint Pre intervention Time 0 Baseline Post intervention 8-month follow-up 12-month follow-up
Enrolment:
Eligibility screen X
Informed consent X
Allocation X
Interventions:
rtfMRI NFT + TAU X
TAU X
Assessments:
Alcohol Timeline Followback X X X X X
Drinking Urges Questionnaire X X X X
Obsessive Compulsive Drinking Scale X X X X
Alcohol Stroop Test X X X X
Severity of Alcohol Dependence X
Thought Control Questionnaire X
Thought Control Ability Questionnaire X
Profile of Mood States X X X
Hospital Anxiety and Depression Scale X X X X
Beck Depression Inventory X X X X
rtfMRI real-time functional magnetic resonance imaging, TAU treatment as usual
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period from the baseline assessment to the present), the
Alcohol Stroop Test (only after the last training session);
the OCDS (only after the last training session); the HADS
(only at the last training session); the BDI (only at the last
training session); a debriefing interview questionnaire to
identify strategies that participants used to down-regulate
their brain reactions to alcohol stimuli (and up-regulate
their brain responses to other goal-related pictures), their
general experience with the procedure, and any adverse
reactions that they might have experienced.
Four-month assessment of the control group
Four months after their baseline assessment, patients in
the control group complete the Alcohol TLFB (covering
the period from the baseline assessment to the present),
the NHS resource utilisation questionnaire, the Drinking
Urges Questionnaire, the Alcohol Stroop Test, the
OCDS, and the POMS.
Follow-up assessments
Eight and 12 months after the baseline assessment, both
the experimental group and the control group are ad-
ministered the Alcohol TLFB (covering the period from
the previous assessment to the present), the NHS re-
source utilisation questionnaire, the Drinking Urges
Questionnaire, the Alcohol Stroop Test, the OCDS, the
POMS, the HADS, and the BDI.
BRAINTRAIN core outcome measures
Some of the assessment instruments named above are
part of the BRAINTRAIN core outcome measures, i.e.
they are given in all five of the centres involved in the
BRAINTRAIN project. Some of them (e.g. those meas-
uring intellectual functioning and thought control) are
used mainly to predict who will perform better at NFT
and benefit more from it clinically. These measures will
be used to stratify patients, and they are largely explora-
tory. Other instruments in this set measure nonspecific
clinical factors and comorbidities (e.g. depression, anx-
iety) and are included across the different trials to in-
crease the power of secondary outcome measures and to
examine nonspecific effects of NFT on mental health
(across different diagnoses and research protocols).
Participants are being sent reminders to attend the
follow-up sessions.
Whenever possible, outcome data will be collected for
all participants whether or not they adhere to the
planned intervention. The data will be analysed accord-
ing to the intention-to-treat principle.
Intervention
During the baseline assessment, participants also perform a
computer-based rating task, in which they are presented
with a total of 100 pictures showing different categories of
alcoholic beverages (wine, beer, spirits, etc.) and pub scenes
and 100 pictures illustrating alternative, healthy goals (posi-
tive personal relationships, health and fitness, employment
and career, further education/self-improvement, and per-
sonal finances). For each alcohol-related picture, partici-
pants are asked to indicate (by using the mouse to move
the cursor along a visual analogue scale on the screen) how
much this specific picture makes them want a drink of al-
cohol; response options range from not at all to very
strongly. Using the same response modalities, participants
Table 2 Standardised measures administered
Measure Description
Alcohol Timeline Followback (TLFB) Questionnaire [13];
primary outcome measure
Measures alcohol use during the 4 months immediately prior to patients’ entering
treatment
Drinking Urges Questionnaire [22];
secondary outcome measure
Assesses participants’ desire to drink, expectations of positive effects following drinking,
relief of withdrawal and negative affect following drinking, and intentions to drink
Obsessive Compulsive Drinking Scale (OCDS) [23];
secondary outcome measure
Measures respondents’ obsessive thoughts about alcohol use and compulsive
behaviours related to drinking
Alcohol Stroop Test [24]; secondary outcome measure Measures alcohol-related attentional distraction by alcohol-related stimuli
Severity of Alcohol Dependence Questionnaire [25];
primary outcome measure
Measures the degree to which patients are physically and psychologically
dependent on alcohol
Thought Control Questionnaire (TCQ) [26];
BRAINTRAIN core outcome measure
Assesses the effectiveness of strategies used to control unpleasant or unwanted
thoughts
Thought Control Ability Questionnaire (TCAQ) [27];
BRAINTRAIN core outcome measure
Measures individuals’ perceived ability to control unwanted and intrusive thoughts
Profile of Mood States (POMS) [28];
BRAINTRAIN core outcome measure
Measures anger, confusion, depression, fatigue, tension, and vigour
Hospital Anxiety and Depression Scale (HADS) [29];
BRAINTRAIN core outcome measure
Measure anxiety and depression
Beck Depression Inventory (BDI) [30]; BRAINTRAIN core
outcome measure
Measures depression
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rate each of the pictures related to an alternative goal with
regard to how much it reminds them of a positive goal that
they are currently pursuing. For each of the subsequent
NFT sessions in which alcohol-related pictures are down-
regulated or alternative goal-related pictures are up-
regulated, the pictures are randomly selected from the 14
pictures in each category that the participant rated most
highly. Thus, the stimulus sets are tailored to each partici-
pant’s specific drinking preferences and hierarchy of alter-
native goals.
The NFT involves magnetic resonance imaging (MRI)
during which patients lie on a movable bed inside the bore
of an MRI scanner. Before entering the MRI suite, patients
undergo a detailed MRI safety screening (as described
earlier), including a determination of potential safety haz-
ards (see exclusion criteria) and the removal of all metal
objects, such as keys or jewellery, from their body.
While in the scanner, participants in the experimental
group are again exposed to alcohol-related stimuli, such
as pictures of alcoholic drinks, and they are trained to
regulate their responses in specific brain regions that are
activated by the stimuli. In addition, participants are ex-
posed to pictures showing alternative, socially desirable
goals, such as family/relationships or employment. The
rationale for including the two categories of stimuli is
that we earlier demonstrated at a neural level that heavy
drinking is associated with overvaluation of alcohol and
undervaluation of alternative, socially desirable goals
[14]. Moreover, consistent with motivational theory [15–
17], it has been shown that problem drinkers’ success in
reducing their drinking is associated with the degree to
which they have other satisfying alternative goals to pur-
sue and enjoy [16].
The size of the images that participants see corre-
sponds to the level of activation. They are told to use
any kind of mental strategy at their disposal (e.g. think-
ing about the negative consequences of drinking) that
helps to reduce size of the image (in the case of alcohol
pictures) or increase size of the image and thereby the
degree of brain activation (in the case of healthy, goal-
related pictures).
Experimental participants have six NFT training ses-
sions spread across 4 months, and they are also asked to
practice at home the mental strategies they used in the
MRI scanner. They also (1) rate their urges to drink be-
fore, during, and after each training session, and (2)
complete questionnaires and other tests to measure their
alcohol consumption and other relevant aspects of their
behaviour. Control participants complete the same mea-
sures that are timed to coincide with their administra-
tion to the experimental group. The primary outcome
measures are obtained 4 months after the baseline as-
sessment. Eight and 12 months after baseline assessment
both groups complete a follow-up assessment battery.
For the duration of the scanning session, several add-
itional physiological parameters are measured, including
heart rate via a finger pulse sensor and respiratory rate
via a belt affixed to the participant’s chest. Participants
are able to see outside the scanner during the scan, and
radiographers are able to see and monitor participants
from the control room. Participants are given a call but-
ton to press if they need to communicate with someone
outside the scanner. The scan can be stopped at any
time at a participant’s request (e.g. if he or she feels un-
comfortable) or if the radiographer becomes concerned
about a participant’s wellbeing.
Imaging data are acquired using the 3T General Electric
HDx or Siemens Prisma scanners at the Cardiff University
Brain Research Imaging Centre (CUBRIC) and standard
parameters for functional and structural brain imaging.
Blood oxygenation level-dependent (BOLD) signals during
localiser and neurofeedback runs (see description below)
are measured with a T2*-weighted gradient echo planar
imaging (EPI) sequence that is synchronised to the onset
of the stimulus presentation. Each functional EPI volume
contains 24 slices of 2.5-mm thickness, with 0.5-mm
inter-slice spacing (in-plane resolution = 3 mm, matrix
size = 64 × 64, FoV (field of view) = 192 mm, TR (repeti-
tion time) = 1500 ms, TE (echo time) = 30 ms, flip angle =
80°, orientation = transversal). High-resolution structural
images are acquired before the first functional scan using
a fast spoiled gradient echo sequence (FSPGR) with 172
contiguous sagittal slices of 1-mm thickness (voxel size:
1 × 1 × 1 mm, TR = 7.9 s, TE = 3.0 ms, flip angle = 20°,
FoV = 256 × 256 × 172 mm).
The basic neurofeedback setup being used in the trial is
illustrated in Fig. 2. Patients are asked to lie still through-
out the scanning sessions; they are in the scanner for no
longer than 90 min. During the scan, patients are exposed
to pictorial stimuli (depicting either alcoholic drinks or al-
ternative goals), which are projected onto a screen behind
the scanner and viewed through a mirror attached on the
MRI head coil. Functional MRI (fMRI) data are acquired
in short blocks (runs) having a duration of 7.5 min. The
first run serves as the localiser procedure in which we
present in alternating blocks of 30-s alcohol-related pic-
tures or goal-related pictures and neutral pictures (house-
hold objects). Each block contains 15 different pictures of
the same category (2 s per picture) and is followed by a
fixation (rest) period. Participants are instructed to atten-
tively watch the pictures without any cognitive/emotional
regulation of the responses that are elicited by these pic-
tures. Based on real-time preprocessing and statistical
analysis of the BOLD signal recorded during the localiser,
a specific target brain area (either alcohol- or goal-related)
is individually selected for each participant in each session.
Statistically significant regions of interest (ROIs) are se-
lected using a t-contrast of alcohol/goal-related versus
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neutral images, and a variable t-threshold to ensure that a
robust cluster is activated in a functionally relevant area
(minimum of four connected voxels).
The next four runs consist of two NFT runs, during
which the participant attempts to self-regulate activation
in the target area, and two mirror (M) runs in the order
NFT-M-NFT-M. During mirror runs, the previous
feedback-modulated stimulus is presented, but partici-
pants are instructed to passively view it and not attempt
to regulate their response. These runs serve as a control
for potential low-level image size effects on activation in
the target area. They will allow a comparison to be made
between the same stimulus presentation with and with-
out attempted self-regulation. Selection of both sets of
pictures is based on the computer-based rating task that
the participant performed during the baseline session.
Each neurofeedback run consists of seven regulation
blocks of 30-s duration showing one picture exemplar
whose size changes according to the participant’s BOLD
activation in the target area. Between regulation blocks,
a 30-s resting block showing a fixation cross is inter-
spersed, and each run begins with a 30-s rest block.
Feedback is provided by varying the size of the picture,
which can range from between 100 % of the entire pro-
jector screen (1024 × 768 pixels) and 10 % of the screen,
depending on the level of activation.
Down-regulation is signalled by decreasing the size of
the picture, following a procedure piloted by our re-
search group for food-related stimuli [18]. Up-regulation
(during exposure to other goal-related pictures) is sig-
nalled by increases in the size of the picture. The aspect
ratio of the pictures is kept constant for all picture sizes.
The size of the picture is changed based on the
percentage of the signal change in the current block
compared to the baseline in the previously defined ROI.
The last five volumes prior to the current neurofeedback
block are used to calculate the baseline level.
A moving average filtre of four volumes is used to
overcome spikes and signal drops and to avoid large
fluctuations in the size of the pictures. The percentage
signal change is calculated using this equation:
f b ¼ val−blð Þ=bl  100
The percentage signal change (PSC) is then normalised
to a value between −1 and +1 by dividing the fb value by
a predefined maximum PSC of 1 %. This is done in
order to be able to resize the pictures in the predefined
way.
Between the fMRI runs, the experimenter speaks to
the participant using an intercom and gives the partici-
pant the opportunity to rest. Participants in the control
group are invited to attend four behavioural assessment
sessions (baseline assessment, primary assessment after
4 months, and a follow-up assessment after 8 and 12
months).
All adverse events and serious adverse events (SAEs)
will be recorded on the appropriate Case Report Form.
Events meeting the criteria for a SAE will be reported
according to the timelines specified in the study protocol
(e.g. an SAE form should be completed for all SAEs
within 24 h).
Post trial, all participants will remain under the care of
their primary treating physician. Cardiff University will
provide indemnity and compensation in the event of a
claim by a participant, or by someone on a participant’s
Fig. 2 Illustration of the neurofeedback setup used in the intervention group. Participants receive real-time feedback about the computed activation level
in target areas that have been identified in a preceding localiser scan as key components of the motivational network involved in alcohol-cue reactivity.
Activation levels are represented as varying picture sizes, with decreasing picture sizes reflecting successful down-regulation
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behalf, for negligent harm as a result of the study design
and/or in respect of the protocol authors/research team.
Cardiff University does not provide compensation for
non-negligent harm.
Sample size estimation
There are no published randomised trials to inform a
sample size calculation for the early phase efficacy trial
of the neurofeedback intervention that is being evalu-
ated. However, experimental neurofeedback studies have
found large effect sizes of 0.5 to 1.5, depending on the
patient group that was tested [5, 6]. At a significance
level of 0.05, the present sample size (from which we ex-
pect a 20 % dropout rate, yielding a final size of 40 (or
20 in each group)) will allow us to detect effect sizes
ranging from 0.8 with 70 % power to 1.1 with 90 %
power. This level is suitable for single-site, early-phase
detection of clinically promising results.
Analyses
One of the study investigators will perform data entry,
and a second member of staff will compare the database
record (the electronic Case Report Form; eCRF) with the
source record (the paper Case Report Form; pCRF).
pCRFs will be stored securely in locked filing cabinets,
and the data in the eCRFs will be stored securely in the
database housed at Cardiff University. Access to the
database is restricted to named study team personnel
only and in accordance with their specific roles and re-
sponsibilities. The data management plan will contain all
relevant details about how the data for the study are be-
ing handled and managed.
The study site statistician, the principal investigator
(PI), and the trial unit statistician will have access to the
final dataset for study site-specific analyses and meta-
analyses across the sites in BRAINTRAIN. The analysis
population will be on an intention-to-treat basis (as ran-
domised) using complete data. We do not intend to per-
form imputation for missing data in this early phase
study but will check for bias in any missing cohort.
The anatomical and functional brain imaging data will
be analysed using BrainVoyager (http://www.brainvoya-
ger.com) or another appropriate software package. A
general linear model will be used to test the effects of
NFT on brain activation, both in target areas and at the
whole-brain level. Specifically, we will contrast activation
in neurofeedback runs with passive viewing during the
perceptual control (mirror) runs. We expect to find re-
duced activation during neurofeedback in the target and
other craving-related areas, but increased activation in
other areas, e.g. those related to emotional control or
which represent alternative, socially desirable goals (in
the runs that include the goal-related pictures). Partici-
pants’ improvement in self-regulation across the sessions
will be analysed using brain-activation parameters in re-
peated the correct term is definitely measures (with an
"s") NOT measure. Analyses of variance (ANOVAS). The
ability to self-regulate will also be correlated with online
and offline craving scores obtained during each session.
The behavioural data will be analysed using SPSS or
another appropriate statistical software package. The pri-
mary analyses will compare the experimental and con-
trol groups on three drinking indices (percentage of days
abstinent, drinks per drinking day, and percentage of
days of heavy drinking) at the primary endpoint (4
months after the baseline assessment). For these ana-
lyses, a general linear model will be used. Covariates will
include potential variables that determine participants’
success with the NFT (e.g. their age and gender and
drinking indices at baseline) and the variables that were
used to balance the two groups during randomisation.
Effect sizes for the intervention will be evaluated using
confidence intervals around the group difference. Ana-
lyses will be conducted separately for the follow-up as-
sessments, again using general linear models adjusted
for baseline covariates and randomisation variables. Out-
come measures related to craving will be evaluated for
both immediate and sustained effects of the NFT.
In exploratory analyses, data from the homework diar-
ies will be examined for a potential relationship between
the amount of self-regulation practice that participants
report and their scores on craving and alcohol consump-
tion. Finally, the relationship between nonalcohol-related
measures (e.g. thought control ability, intellectual ability)
and the alcohol-related outcome measures will be exam-
ined using analysis of covariance (ANCOVA) or correl-
ational and regression analyses. Nonspecific effects of the
NFT on participants’ mood will be examined using the
measures related to emotional processes (e.g. the POMS).
A publication policy will be developed and reviewed
during the course of the trial, which will include details of
dissemination plans to health care professionals. Publica-
tions from the BRAINTRAIN consortium will be coordi-
nated by the Executive Committee of BRAINTRAIN
(chaired by the PI) in collaboration with the funding organ-
isation. The trial results will be submitted for publication in
an online open access journal.
Discussion
Alcohol dependence is a recalcitrant disorder, with high
rates of relapse to heavy drinking occurring following
treatment [19, 20]. In recent years, new medications and
psychosocial interventions have been tested, but with
disappointing effects on rates of relapse [19]. In view of
the encouraging results obtained with rtfMRI NFT in
the case of other psychiatric and behavioural disorders
[4–9], its use in the treatment of alcohol dependence of-
fers great promise.
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The present study allows us to evaluate the overall
effectiveness of rtfMRI NFT in reducing patients’
urges to drink and various indices of their alcohol
consumption. Additionally, we will be able to evaluate
participant characteristics (e.g. the ability to control
thoughts, anxiety, depression, intellectual ability) that
help to determine patients’ degree of success with the
intervention. If positive results are obtained, more
cost-effective techniques for helping patients to
achieve self-control over their alcohol consumption
could be developed and evaluated. Moreover, the use
of these techniques could be extended to include early
stage problem drinkers. Early stage problem drinkers
are far more numerous in society than are dependent
drinkers, yet dependent drinkers are far more costly to
treat [21]. Thus, it could be highly effective and cost-
effective to successfully intervene with people who are
developing alcohol problems before these problems
escalate into dependent drinking.
Trial status
This trial is ongoing and participants are being actively
recruited.
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Additional file 1: SPIRIT checklist. (DOC 124 kb)
Additional file 2: Consent Form (both groups). (DOCX 403 kb)
Additional file 3: Consent Form (MRI training). (DOCX 132 kb)
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rtfMRI: Real-time functional magnetic resonance imaging
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